Viread® For Hepatitis B Registration In The Developing World

Approved

1.	Albania	July 2011
2.	Anguilla	June 2011
3.	Antigua and Barbuda	June 2011
4.	Argentina	May 2011
5.	Armenia	September 2011
6.	Aruba	September 2011
7.	Azerbaijan	May 2011
8.	Bahamas	June 2011
9.	Bangladesh	June 2011
10.	Barbados	June 2011
11.	Belarus	December 2013
12.	Belize	June 2011
13.	Bhutan	November 2012
14.	Bolivia	September 2011
15.	Bosnia and Herzegovina	June 2012
16.	Brazil	December 2010
17.	British Virgin Islands	June 2011
18.	Burkina Faso	September 2014
19.	Cambodia	April 2011
20.	Chile	November 2011
21.	Colombia	March 2013
22.	Costa Rica	March 2013
23.	Cuba	June 2011 *
24.	Curacao	October 2011
25.	Dominica	June 2011
26.	Ecuador	August 2012

27. Egypt	March 2012
28. Ethiopia	August 2015
29. Fiji	June 2011
30. Gabon	November 2014
31. Georgia	June 2011
32. Grenada	June 2011
33. Guatemala	June 2011
34. Guinea	February 2014
35. Honduras	July 2012
36. India	December 2011
37. Iran	April 2012
38. Kazakhstan	May 2012
39. Kenya	September 2014
40. Kiribati	June 2011
41. Kosovo	June 2011
42. Kyrgyzstan	July 2012
43. Lao, People's Dem. Rep	January 2013
44. Mali	November 2014
45. Mexico	November 2012
46. Moldova	January 2013
47. Mongolia	September 2014
48. Montserrat	June 2011
49. Myanmar	December 2012
50. Namibia	August 2015
51. Nauru	June 2011
52. Nepal	September 2014

53. Niger	March 2014
54. Pakistan	January 2013
55. Palau	June 2011
56. Panama	February 2012
57. Paraguay	September 2011
58. Peru	June 2011
59. Philippines	March 2014
60. Saint Kitts and Nevis	June 2011
61. Saint Lucia	June 2011
62. Saint Vincent & the Grenadines	June 2011
63. Samoa	June 2011
64. Solomon Islands	June 2011
65. Syria	April 2013
66. Tanzania	August 2015
67. Thailand	May 2013
68. Timor-Leste	June 2011
69. Tonga	June 2011
70. Turkmenistan	April 2014
71. Turks and Caicos	June 2011
72. Tuvalu	June 2011
73. Ukraine	September 2012
74. Uruguay	April 2011
75. Uzbekistan	May 2011
76. Vanuatu	June 2011
77. Zimbabwe	July 2015

Filed

1.	Cameroon	May 2014
2.	Central African Republic	June 2014
3.	Chad	November 2014
4.	Congo	May 2014
5.	Côte d'Ivoire	July 2014
6.	Dominican Republic	October 2015

El Salvador	June 2011
8. Guyana	January 2012
9. Jamaica	January 2011
10. Malawi	April 2014
11. Malaysia	December 2013
12. Mauritania	March 2014

13. Senegal	February 2014
14. South Africa	December 2013
15. Tajikistan	August 2011
16. Uganda	February 2014
17. Vietnam	February 2014
18. Zambia	September 2015

Last updated December 2015 www.gilead.com

Pending Submission

1.	Afghanistan	16. Indonesia	31. Rwa	anda
2.	Algeria	17. Iraq	32. São	Tom
3.	Angola	18. Jordan	33. Sey	chell
4.	Benin	19. Lesotho	34. Sier	ra Le
5.	Botswana	20. Liberia	35. Som	nalia
6.	Burundi	21. Libya	36. Sou	ıth Sı
7.	Cape Verde	22. Madagascar	37. Sri l	Lanka
8.	Comoros	23. Maldives	38. Sud	lan
9.	Congo, Dem. Rep. of the	24. Mauritius	39. Suri	inam
10	. Djibouti	25. Montenegro	40. Swa	azilar
11.	. Equatorial Guinea	26. Morocco	41. Tog	O
12	. Eritrea	27. Mozambique	42. Trin	idad
13	. Gambia	28. Nicaragua	43. Tun	isia
14	. Ghana	29. Nigeria	44. Yen	nen
15	. Guinea-Bissau	30. Papua New Guinea		

31. Rwanda
32. São Tomé and Príncipe
33. Seychelles
34. Sierra Leone
35. Somalia
36. South Sudan
37. Sri Lanka
38. Sudan
39. Suriname
40. Swaziland
41. Togo
42. Trinidad and Tobago
43. Tunisia

Terms and Definitions

Approved: Dossier submitted and approved by country or no formal regulatory process in place; approval confirmed by country.

Filed: Dossier submitted and review pending.

Pending Submission: Dossier has not been submitted to date; standard dossier filed - specific documentation required in order to further application process; or all relevant documentation provided to distributor for in-country submission (submission may be pending translation into local language).

Asterisk (*): Product available through distributor.

Note

There can be no guarantee that marketing approval for Viread® for the treatment of hepatitis B will be granted in any of the low- and middle-income countries where registration is pending; any marketing approval, if granted, may have significant limitations on its use.

